Network Bio Launched Thursday August 20, 2026 With $50 Million in Series A Financing to Build AI Models Trained on Human Biological Data for Drug Discovery, Adding to the Rapidly Expanding AI-Driven Peptide and Biologic Discovery Ecosystem That Also Includes PeptiDream's PDPS Platform (Constrained Cyclic Peptide Focus, Partnerships With Novartis, Merck, Genentech, AbbVie, Eli Lilly), Insilico Medicine's Pharma.AI (31 Developmental Candidates, $2.75 Billion Lilly Deal + $2.5 Billion SK Deal + Takeda Collaboration), Aizen Therapeutics' DaX Foundation Model (August 15 Deal With San Diego Public Biotech Worth Up to $100 Million per Target for Oral Peptide Therapeutics), and Isomorphic Labs (Google DeepMind Spinout With AlphaFold-Derived Structural Modeling); The AI Drug Discovery Category Has Accumulated More Than $8 Billion in Partnership Deal Value Across 2026 to Date
Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.